ArticleClinical rheumatology2006
Relationship between serum levels of macrophage migration inhibitory factor and the activity of antineutrophil cytoplasmic antibody-associated vasculitides.
Article in Clinical rheumatology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 27 citations in OpenAlex.
- Plasma Macrophage Migration Inhibitory Factor as a Biomarker of Thromboinflammatory Dysregulation in Anti-Neutrophil Cytoplasmic Antibody- Associated Vasculitis.Archives of rheumatology · 2026Article
- Macrophage migration inhibitory factor is involved in antineutrophil cytoplasmic antibody-mediated activation of C5a-primed neutrophils.BMC immunology · 2019Article
- Macrophage migration inhibitory factor promotes renal injury induced by ischemic reperfusion.Journal of cellular and molecular medicine · 2019Article
- Role of Macrophage Migration Inhibitory Factor in Granulomatosis With Polyangiitis.Arthritis & rheumatology (Hoboken, N.J.) · 2018Article
- Vasculitis Pathogenesis: Can We Talk About Precision Medicine?Frontiers in immunology · 2018Review
- Macrophage Migration Inhibitory Factor in Clinical Kidney Disease.Frontiers in immunology · 2016Review
- Serum macrophage migration inhibitory factor levels in Hashimoto's thyroiditis; a case control study.Thyroid research · 2014Article
- Macrophage migration inhibitory factor (MIF) and thyroid hormone alterations in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV).Molecular medicine (Cambridge, Mass.) · 2013Article
- Development of outcome measures for large-vessel vasculitis for use in clinical trials: opportunities, challenges, and research agenda.The Journal of rheumatology · 2011Article
- Macrophage migration inhibitory factor: a multifunctional cytokine in rheumatic diseases.Arthritis · 2010Article
- Increased serum levels of macrophage migration inhibitory factor (MIF) in patients with microscopic polyangiitis.Open access rheumatology : research and reviews · 2009Article
- Macrophage migration inhibitory factor may contribute to vasculopathy in systemic sclerosis.Clinical rheumatology · 2008Article
- Increased serum levels of macrophage migration inhibitory factor in patients with primary Sjögren's syndrome.Arthritis research & therapy · 2007Article
- Elevated serum macrophage migration inhibitory factor (MIF) concentrations in chronic kidney disease (CKD) are associated with markers of oxidative stress and endothelial activation.Molecular medicine (Cambridge, Mass.)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Macrophage migration inhibitory factor (MIF) is a central proinflammatory cytokine that regulates innate and adaptive immune responses. To evaluate its role in primary vasculitides, we determined MIF by enzyme-linked immunoassay in the sera of patients with Wegener's granulomatosis (WG; n=26), microscopic polyangiitis (MPA; n=10), polyarteritis nodosa (PAN; n=9) and giant cell arteritis (GCA; n=11). Healthy controls (n=26) and patients with sarcoidosis (n=14) were studied in parallel. Serum levels of MIF were significantly higher in patients with WG (median 41.1, range 3.2-120 ng/ml) than those in healthy controls (6.0, 0.015-36.5 ng/ml; P<0.001) and in patients with sarcoidosis (13.8, 0.015-67.1 ng/ml; P<0.05). MIF values were higher in MPA patients (29.5, 9.9-69.4 ng/ml; P<0.01) in comparison with those in healthy controls. In particular, increased levels of MIF were associated with active disease as assessed by the Birmingham Vasculitis Activity Score. Sequential studies showed decreased levels of MIF after initiation of immunosuppressive therapy, with clinical improvement in WG and MPA patients. In contrast, serum levels of MIF were not significantly elevated in patients with PAN and GCA. The results suggest that MIF contributes to the inflammatory process and correlates with disease activity in antineutrophil cytoplasmic antibody-associated vasculitides.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.